News from BilcareView Past NewsTuesday, December 02, 2008 18:15 IST
Our Bureau, Mumbai Bilcare Global Clinical Supplies (GCS), a leading multi regional provider of clinical trial materials (CTM) services, has expanded its packaging operations and Storage capacities at its Pune, India facility to further strengthen its offering to its global customers. With the current expansion in the facility at Pune, India, the packaging and storage capabilities have increased multifold and the facility can now manufacture, package and distribute CTM through its in-house IVRS. The facility, with its approval from the local FDA as well as the Narcotics Control Bureau, is now fully-equipped to not only manage normal CTM but also controlled drug substances, according to a Bilcare announcement. Mohan Bhandari, chairman & managing director, Bilcare Limited said, "The strategic Global presence and focused offerings, along with unique project management skills and collaborative approach form the tenets of key value to our customers. In these times of ever increasing complexities and cost, our innovative offerings are providing synergistic impetus to the pharma innovators who are seeking supportive innovations for enhancing their untiring efforts to bring out newer and safer life saving drugs." "Bilcare GCS continually strives to meet the market demand and has undertaken operations modernization & technology up-gradation of its facilities in USA and UK and now in India. This will significantly enhance the capability of sponsors to conduct clinical trails across the world inclusive of Asia with desired alacrity," says Ajit Dubhashi, president, Bilcare GCS, Asia Pacific. The facility at Pune, India was commissioned in October 2005 making it the first major operation for providing CTM in India. Subsequently, Bilcare GCS has expanded its operational and distribution capabilities of facilities in Pennsylvania, USA and Powys, UK. Bilcare GCS also significantly strengthened its distribution capabilities across the world with its recent formal working agreement with World Courier, a leading specialty logistics company with cold chain expertise. PHOENIXVILLE, Pa. — November 6, 2008 — In its endeavor to accelerate the drug development process cycle and help clients increase their speed to market, Bilcare Global Clinical Supplies, a leading single-source provider of clinical trial supplies and services, has enhanced its ability to develop functionally viable and innovative formulation dosage forms for pre-clinical and early-phase drugs.
According to Vincent Santa Maria, president of Bilcare GCS, Americas, the addition of new technology – which includes state-of-the-art fluid bed granulation and enhanced capsule-filling equipment – is part of the company’s capital investment program in its U.S. facilities. “With these upgrades, Bilcare GCS can now quickly produce a wider variety of drug dosage forms with high product quality at or above industry standards,” he said. “These investments in R&D services further prove our commitment to being a full-service partner to our global customers.” Praful Naik, Ph.D., chief scientific officer of Bilcare Limited, said, “These enhancements complement the increasing number of investigational new drug (IND) applications submitted by innovator pharma and biotech companies, which in turn requires multi-pronged expertise in formulation and analytical research and development.” The fluid bed granulation technology extends Bilcare’s solid-dosage formulation capabilities. Equipped with Wurster coating inserts, the system enables Bilcare to deliver specialized, high-precision coating processes for granules and non-pareils for the creation of top-quality sustained- and controlled-release tablet and capsule formulations. The In-Cap® capsule system, capable of filling several thousand capsules per hour in multiple permutations, is a versatile tool for pre-clinical and early-stage development. This equipment extends both development and clinical manufacturing capabilities for a myriad of formulation types including powders, pellets, tablets and liquids. “Bilcare’s R&D center can now develop a broad array of dosage forms with innovative delivery mechanisms that exceed those developed by pharmaceutical companies,” says Frank Santillo, Ph.D., Bilcare GCS’ senior director for research services. “Most importantly, we now have the expertise to take a drug candidate from concept to clinical production without the client suffering critical and costly delays as a result of hand-offs.” About Bilcare Global Clinical Supplies Bilcare Global Clinical Supplies serves the Americas, Europe, and Asia with clinical trial materials support, services, and complete project management. Its services for solid, semi-solid, liquid, DEA (CI-V), and biotech clinical trial materials (CTM) satisfy a broad range of requirements, from pre-formulation research and development, manufacturing, analytical services and clinical supplies packaging and labeling, to IVRS, QP services, controlled temperature (cold chain) CTM storage, worldwide distribution, and returns and destructions accountability. For more information about Bilcare Global Clinical Supplies, visit www.BilcareGCS.com. In-Cap is a registered trademark of Dott. Bonapace & C. s.r.l. # Media Contacts: Deborah Buscarino Director, Marketing & Communications Phone: 610-422-3204 , Megan Maguire Kelly Schubert Communications Inc. Phone: 610-269-2100 x225 PHOENIXVILLE, PA — October 24, 2008 — Furthering its commitment to satisfying a worldwide customer base, Bilcare Global Clinical Supplies, a leading single-source provider of clinical trial supplies and services, has substantially expanded its global distribution and warehousing capabilities for clinical trial supplies.
Bilcare GCS has formalized its working relationship by signing a service agreement with World Courier to utilize depots in Argentina, Brazil, Colombia, Chile, Mexico, Peru, and Russia. The new locations supplement Bilcare’s existing network with locations in India, U.K., Singapore and the United States. Additional global depot locations are planned for the near future. “With the drug discovery program leading to potential new drugs becoming more complex, the need to clinically test drug efficacy and safety in diverse population groups across multiple geographic regions is becoming a crucial necessity. This necessity is driving clinical trials to be conducted at multiple locations across the globe. Bilcare, as a clinical trial supplies, services and solutions partner to the pharmaceutical industry, envisions and proactively creates the availability of key resources for its patrons, enabling realization of their imminent needs,” commented Mohan Bhandari, Chairman and Managing Director of Bilcare Limited. Vincent Santa Maria, President of Bilcare GCS, Americas, expressed that the successful culmination of this important initiative with World Courier into a formal working collaboration has resulted in augmenting Bilcare’s ability to seamlessly execute international transactions, including customs and door-to-door delivery, all on a local level. This means clear communication, so there are no delays for sponsors, physicians or patients. The World Courier depot sites offer a full range of storage and distribution services including cold chain, which strengthen Bilcare’s capabilities and capacities at its worldwide manufacturing and distribution locations. By entering into a formal working relationship with World Courier, Bilcare will be able to significantly enhance its capabilities globally, to receive, control, verify and store client materials in temperature-controlled facilities providing specialty storage conditions, pick-and-pack handling, and certified delivery to client-designated locations. About World Courier Incorporated in 1969 and headquartered in Stamford, Connecticut (USA) World Courier is the largest and most experienced specialty courier service with a network of over 140 company-owned ISO 9001-certified offices operating in 50 countries worldwide. World Courier has set the benchmark for worldwide time-sensitive transportation and is the acknowledged leader in delivering customized solutions, cold chain and value-added services to the bio-pharmaceutical Research and Development community. Through its company-owned offices and agents, World Courier provides door-to-door, customs-cleared service to more than 220 countries and territories. About Bilcare Global Clinical Supplies Bilcare Global Clinical Supplies serves the Americas, Europe, and Asia with clinical trial materials support, services, and complete project management. Its services for solid, semi-solid, liquid, DEA (CI-V) and biotech clinical trial materials (CTM) satisfy a broad range of requirements; from pre-formulation research and development, manufacturing, analytical services and clinical supplies packaging and labeling, to IVRS, QP services, controlled temperature (cold chain) CTM storage, distribution worldwide, and returns and destructions accountability. For more information about Bilcare Global Clinical Supplies, visit www.BilcareGCS.com. Media Contacts: Deborah Buscarino Megan Maguire Kelly Director, Marketing & Communications Schubert Communications Inc. Phone: 610-422-3204 Phone: 610-269-2100 x225  Bilcare Research Receives Best New Product Award for Innovatiavae Blister Packaging Solution to Brand ChallengesBilcare’s “Innovative Metalized Film Range” reached a milestone on October 1 when it received the award for best new product at the 2008 European Outsourcing Awards in Frankfurt, Germany. The Best New Product Award recognized the metalized film and the value it adds to the global pharmaceutical market. The film addresses counterfeiting and creates a distinct brand identity for drugs packaged in it. Ultimately, it helps consumers take the right medicine every time by providing a distinct feature on every drug packaged in the film. Judges stated that this novel product will bring about a positive change in mindset in the pharmaceutical sector.Press Release Innovation Abounds at EOA 2008 October 1, 2008 - Recently dubbed the "Outsourcing Oscars" by judge and presenter Dr Makarand Jawadekar of Pfizer Global R&D, the best and most innovative partnerships and relationships were honoured again this year at the European Outsourcing Awards (EOA) 2008 gala dinner. Launched in 2005, the European Outsourcing Awards recognizes significant developments in contract services and rewards successful companies for their outstanding contributions and achievements throughout the year. The awards were created to celebrate and recognize excellence in R&D, marketing, business and technology across the pharmaceutical industry. This year, more than 180 people attended the prestigious ceremony at Frankurt's Steigenberger Frankfurter Hof Hotel on the 1st of October, and were treated to a lavish meal before the lights were dimmed and the golden envelopes were opened. Compered by Mr Rodney Steel, Chief Executive of the British Contract Packers and Manufacturers Association and Mrs Catherine Gonon, Executive Director of the SFSTP, ten awards were presented for categories such as Best New Product, Best Contract Manufacturing Project, and Most Outstanding Applications in Nutraceuticals and Most Innovative Relationship. Head of the judging panel and Via Media's Editorial Director, Dr Kevin Robinson, said of the competition: "The judging panel had a tough job this year. We received a record number of nominations and, overall, the quality was excellent. The EOA is establishing itself as a showcase for innovation and talent in the contract services sector. I'd like to sincerely thank all the companies who submitted an entry ... and all the judges for rigorously assessing them. We wouldn't have an event without them." Simon Jones, Managing Director of Via Media Ltd, added: "The EOA has become a prestigious occasion and a mustattend event for the outsourcing sector. We're very grateful for the support of our sponsors and partners, and we're very much looking forward to the next event in Madrid in 2009." Patrick Hughes of Exco Intouch, recipient of the Best IT Strategy award added that the company was "Delighted and really proud to be a winner." Terry Novak, President of North America and Chief Marketing Officer, stated: "Patheon is proud to have won the Most Effective Scale-Up and Technical Transfer award at this year's European Outsourcing Awards. Our performance in the industry is being recognized for a reason: we have dedicated ourselves to understanding our customer's needs and developing both the capability and capacity to deliver on those needs. It's rewarding to even be considered with Procter and Gamble for this award by other industry leaders." In closing, Event Director and Publisher of Pharma Magazine, Miranda Docherty, stated: "Since its launch in 2005, I’m delighted to have played an integral role in the growth and development of the European Outsourcing Awards. It gives me great pleasure to report that this year’s event has been the best so far and the coming together of so many senior industry figures really highlights the networking value that the evening presents in addition to the Awards." For more information, visit http://www.europeanoutsourcingawards.com/ Additional Primary Packaging Rooms Mark Milestone In Company’s Expansion Program[Phoenixville, PA]Bilcare Global Clinical Supplies, the single source provider for global clinical supplies and services, took another major step in its expansion and modernization program today as it announced the completion and opening of five state-of-the-art primary packaging rooms at its Phoenixville, PA facility. During the fourth quarter of 2007 Bilcare will complete the next phase of upgrades with the release of five additional primary rooms bringing Bilcare to a total of ten primary and sixteen secondary packaging rooms within its 153,000 square foot US operation. “The ongoing expansion and upgrading of our facilities and equipment is part of a comprehensive effort to provide world class service to our customers,” said Bilcare, Inc. President Vincent Santa Maria. “Now more than ever Bilcare has the capability to provide quality beyond compliance.” Over the last several months Bilcare has launched an ambitious program to upgrade its facilities and equipment including increasing the size of its storage and distribution facility to 72,000 square feet; adding six new packaging rooms; upgrading 20 packaging rooms; installing PRISYM Medica label and design production software and bolstering its IVRS capabilities. According to Santa Maria, “Each of these upgrades is designed to demonstrate to customers that Bilcare is a company focused on providing high quality service using cutting edge technology in a modern facility. Customers can be confident that Bilcare will handle their projects in a professional and timely manner.” Bilcare, a true global service provider, has manufacturing, packaging, labeling, storage and distribution facilities in the US, UK, India and Singapore. “With the sophisticated systems required to manage the production and logistics of clinical trial supplies on a global basis, our expanded and upgraded US facilities combined with our strong foothold in India, UK and Singapore, leave Bilcare well-positioned to take advantage of the trend toward global clinical trials,” said Santa Maria. Bilcare Global Clinical Supplies serves the Americas, Europe, and Asia with clinical trial materials support, services and complete project management. Our services for solid, semi-solid, liquid, DEA (CI-V) and biotech clinical trial materials (CTM) satisfy a broad range of requirements; from pre-formulation research and development, analytical services and clinical supplies packaging and labeling, to IVRS, controlled temperature (cold and frozen chain) CTM storage, distribution worldwide, and returns and destructions accountability. We combine our industry experience, total clinical supply chain service and delivery to provide smart, efficient and innovative solutions to every one of our customers. For more information about Bilcare Global Clinical Supplies, please visit our website at http://www.BilcareGCS.com/ Media Contact: Vincent Santa Maria President Bilcare, Inc. 610-935-4300 Fax: 610-935-4321 E-mail: Corporate Information Contact : Jaydip Chowdhury : Head Corporate Communications [] Completes Next Step in Major Global Expansion InitiativeMay 29, 2008—[Phoenixville, PA] Bilcare Global Clinical Supplies, a leading single-source provider of clinical trial services, announced the completion of a major expansion of storage capacity at its warehouse facility in Phoenixville, PA. The expansion immediately doubles ambient storage capacity of its facility. It is the first step of a four phase project that will expand the warehouse and distribution area. All phases of the project will be completed in the third quarter of this year. “The increase in storage capacity is the next step in a series of global upgrades designed to demonstrate to customers that Bilcare is a company focused on providing high quality service and cutting edge technology for its customers to ensure on time project completion,” said Bilcare GCS Americas President Vincent Santa Maria.The storage capacity expansion is another key element of a global expansion initiative Bilcare GCS began in 2007 to provide a higher level of quality and service to its customers. During the last several months, the company has made substantial improvements globally including increasing the number of its state-of-the-art packaging rooms, upgrading equipment, expanding its storage and distribution facilities, enhancing its formulation and analytical development services and technical capabilities, improving its IVRS/IWRS capabilities and integrating global operations. Commenting on the ongoing capital campaign, Bilcare GCS CEO Vito Mangiardi stated, “These capital improvements combined with our experienced project managers and global footprint in the Americas, Europe and Asia signifies that Bilcare GCS is a growing company committed to providing world class service.“ Bilcare Global Clinical Supplies serves the Americas, Europe, and Asia with clinical trial materials support, services and complete project management. Our services for solid, semi-solid, liquid, DEA (CI-V) and biotech clinical trial materials (CTM) satisfy a broad range of requirements; from pre-formulation research and development, manufacturing, analytical services and clinical supplies packaging and labeling, to IVRS, QP services, controlled temperature (cold and frozen chain) CTM storage, distribution worldwide, and returns and destructions accountability. For more information about Bilcare Global Clinical Supplies, please visit our website at BilcareGCS.com. ## Media Contacts: Deborah Buscarino Director, Marketing & Communications Phone: 610-422-3204 Fax: 610-935-4321 Email Contact: Vito Mangiardi Chief Executive Officer Bilcare Global Clinical Supplies Phone: 610-551-2035 Fax: 610-935-4321 Email Contact: New PRISYM Labeling Software Meets FDA Requirements and Saves TimePhoenixville, PA - In its ongoing mission to provide its customers service and quality beyond compliance, Bilcare Global Clinical Supplies http://www.BilcareGCS.com has installed PRISYM Medica label design and production software. Bilcare can print labeling projects in-house, saving customers more than 3 weeks of production time on average when compared to outsourcing. “The installation of PRISYM label software is the latest step in our ongoing effort to continually improve the quality of service we offer our customers,” said Bilcare America’s President, Vincent Santa Maria. “The recent upgrading of our packaging rooms, the expansion of our storage facilities and the enhancement of our IVRS capabilities are all important milestones for Bilcare and our customers.”PRISYM Medica label design and production software is specifically developed to meet the FDA’s current compliance requirements, in particular, 21 CFR Part 11. The software uses high levels of security and data encryption to ensure systems integrity and regulatory compliance at all times. It is able to record critical activities and electronically links them to individual users, along with time and date stamping. This is the same software labeling program used by many large pharmaceutical companies. In accordance with Bilcare’s User Requirement Specification, the software can print labels in up to 32 different languages as fixed text as well as sequentially numbered and randomized labels. PRISYM’s software solution provides additional label project management tools such as reporting capabilities and study specific packaging configuration set-up. PRISYM Medica provides a totally secure environment for label design, approval, automatic gathering of variable data and label printing. It is developed, tested and documented in accordance with strict FDA and GAMP (Good Automated Manufacturing Practice) guidelines and supplied with full life cycle documentation. The PRISYMLS team has over 20 years experience in delivering high quality labeling and auto-identification solutions to companies in a wide range of industries. With offices in the UK and USA as well as an extensive network of international partners worldwide PRISYM has a well established global presence. The global reach of PRISYMLS has positive implications for Bilcare which currently has distribution capability into 50 countries worldwide. Bilcare’s locations in India and Wales will also begin using this software in the near future. Bilcare Global Clinical Supplies serves the Americas, Europe, and Asia with clinical trial materials support, services and complete project management. Our services for solid, semi-solid, liquid, DEA (CI-V) and biotech clinical trial materials (CTM) satisfy a broad range of requirements; from pre-formulation research and development, analytical services and clinical supplies pack-aging and labeling, to IVRS, controlled temperature (cold and frozen chain) CTM storage, distribution worldwide, and returns and destructions accountability. Our integrated approach provides you with seamless service throughout your entire project. We combine our industry experience and our total clinical supply chain service and delivery to provide smart, efficient and innovative solutions. ## Media Contact: Vincent Santa Maria President Bilcare Inc. Phone: 610-935-4300 Fax: 610-935-4321 E-mail: Corporate Information Contact : Jaydip Chowdhury :Head Corporate Communications []  Eddie has more than 30 years of national and international experience in the medical and clinical industry having worked in the Middle East and most recently as IVRS Director for Covance in Princeton, New Jersey. Eddie worked at Covance for more than 12 years during which time he had many noteworthy accomplishments including designing and managing hundreds of IVRS projects and developing the company’s inventory forecasting system, Foresite. As Director of IVRS for Bilcare, Eddie will be responsible leading the expansion of IVRS/IWRS technology in the US and globally for the benefit of Bilcare’s clients. Bilcare Global Clinical Supplies serves the Americas, Europe, and Asia with clinical trial materials support, services and complete project management. Our services for solid, semi-solid, liquid, DEA (CI-V) and biotech clinical trial materials (CTM) satisfy a broad range of requirements; from pre-formulation research and development, analytical services and clinical supplies pack-aging and labeling, to IVRS, controlled temperature (cold and frozen chain) CTM storage, distribution worldwide, and returns and destructions accountability. Our integrated approach provides you with seamless service throughout your entire project. We combine our industry experience and our total clinical supply chain service and delivery to provide smart, efficient and innovative solutions. ## Media Contact: Vincent Santa Maria, President Bilcare Inc. Phone: 610-935-4300 Fax: 610-935-4321 E-mail: Corporate Information Contact : Jaydip Chowdhury :Head Corporate Communications [] SAN FRANCISCO, CA — September 17, 2008 — Bilcare Global Clinical Supplies, a leading single-source provider of clinical trial supplies and services, has completed the expansion of its warehouse and distribution facility in Phoenixville, Pa. Bilcare GCS, Americas’ facility now provides 300 percent more ambient storage capacity, as well as a 50 percent larger distribution pack-out area and a second distribution dock allowing for increased output. “The increase in storage capacity is the latest in a series of global upgrades designed to demonstrate to customers that Bilcare is a company focused on providing high quality service and cutting edge technology for its customers to ensure on time project completion,” said Bilcare GCS Americas president Vincent Santa Maria.
In addition to this latest facility expansion, Bilcare GCS has also enhanced its global operations by adding state-of-the-art packaging rooms, upgrading equipment, and increasing capacity and expanding capabilities in its formulation and analytical development services. The company also expanded its facility in Rajgurunagar, near Pune, India and plans US$21 million expansion toward a new clinical supplies facility in South Wales. Commenting on the ongoing capital campaign, Bilcare GCS CEO Vito Mangiardi stated, “These capital improvements combined with our experienced project managers and global footprint in the Americas, Europe and Asia signifies that Bilcare GCS is a growing company committed to providing world class service.” About Bilcare Global Clinical Supplies Bilcare Global Clinical Supplies serves the Americas, Europe, and Asia with clinical trial materials support, services, and complete project management. Its services for solid, semi-solid, liquid, DEA (CI-V) and biotech clinical trial materials (CTM) satisfy a broad range of requirements; from pre-formulation research and development, manufacturing, analytical services and clinical supplies packaging and labeling, to IVRS, QP services, controlled temperature (cold chain) CTM storage, distribution worldwide, and returns and destructions accountability. For more information about Bilcare Global Clinical Supplies, visit www.BilcareGCS.com. # Media Contacts: Deborah Buscarino Director, Marketing & Communications Phone: 610-422-3204 Vito J. Mangiardi Chief Executive Officer Phone: 415-492-4586 SAN FRANCISCO — September 4, 2008 — As part of its commitment to providing its customers with comprehensive services that span the entire clinical supply chain, Bilcare Global Clinical Supplies, a leading single-source provider of clinical trial supplies and services, has enhanced its global Phase III capabilities. Its latest Phase III investments include the upgrade of its Kalish large-scale bottling line at its U.S. facility and an investment in new Pentapack blistering technology for expanded packaging capabilities in America and Europe.
“Our experiences over the past few years, along with those of our customers, have shown us that the pharmaceutical industry has tired of working with multiple partners during different clinical trial phases,” said Vito Mangiardi, chief executive officer of Bilcare GCS. “The management of numerous partners is cumbersome, and working with varying levels of R&D, quality control, and project and delivery turnaround times can skew a trial’s timeline. By investing in large-scale equipment technology, we’re offering our customers what no other partner can: a true, integrated partnership that can take them from beginning-phase research and development through Phase III.” Bilcare GCS’ investment in the Pentapack CT1200L system allows the company to package high-volume runs for large-scale clinical trials and stability tests. This latest technology gives Bilcare GCS additional flexibility in trial design and execution to meet individual client needs. The Pentapack system enables Bilcare GCS to design blister packaging configurations online using Trialpack Designer II packaging design software, and immediately implement them for production. The machine can produce thermoformed and cold-formed blisters from a variety of materials and features multi-product flood feeding. The vision system checks the content of blisters and verifies accurate product placement before sealing. A programmable cutting station provides the flexibility to meet specific customer demands and match all pharmaceutical standards. The system’s automation significantly reduces manufacturing times and creates a 21 CFR Part 11-compliant electronic paper trail that documents changes from design to production through quality control. “Bilcare GCS has built its reputation on providing customers with the highest quality research services and clinical supplies delivered on time, every time,” said Vince Santa Maria, president of Bilcare GCS, Americas. “The Pentapack and the expanded Kalish lines are key components to taking Bilcare’s Phase III clinical trial services to the next level by leveraging state-of-the art packaging technologies to deliver superior quality products in a highly flexible and efficient manner. These latest investments are further proof of Bilcare’s long-term commitment to serving the industry with exceptional quality and service beyond compliance.” About Bilcare Global Clinical Supplies Bilcare Global Clinical Supplies serves the Americas, Europe, and Asia with clinical trial materials support, services, and complete project management. Its services for solid, semi-solid, liquid, DEA (CI-V) and biotech clinical trial materials (CTM) satisfy a broad range of requirements; from pre-formulation research and development, manufacturing, analytical services and clinical supplies packaging and labeling, to IVRS, QP services, controlled temperature (cold and frozen chain) CTM storage, distribution worldwide, and returns and destructions accountability. For more information about Bilcare Global Clinical Supplies, visit www.BilcareGCS.com. # Media Contacts: Deborah Buscarino Director, Marketing & Communications Phone: 610-422-3204 Megan Maguire Kelly Schubert Communications Inc. Phone: 610-269-2100 x225 San Francisco, CA – July 31, 2008 — Bilcare Global Clinical Supplies, a leading single-source provider of clinical trial services, announced that it has opened its new global U.S. headquarters in San Francisco. The headquarters, which will be led by CEO Vito Mangiardi, operates as the company’s corporate hub to drive growth in Bilcare’s American, European, and Asian regions.
“This year has been one of substantial growth in every area of our global business, from staffing and facilities to equipment and services,” said Mangiardi. “While our U.S., India, and Wales-based facilities manage the increased demand for research and packaging services, our headquarters will dedicate itself to furthering global integration and growing the company as a full-service solutions provider that can take customers from research and development, to Phase I and II trials, and through longer-term Phase III trials.” The opening of Bilcare GCS’ global headquarters marks the latest development in the company’s significant growth. During its 2007-2008 fiscal year, Bilcare GCS nearly doubled its global workforce, including significant additions to its executive team; completed a US$2.3 million capital investment program in the U.S.; expanded its facility in Rajgurunagar, near Pune, India; plans US$21 million towards a new clinical supplies facility in South Wales; and made significant global investments in technology, project management, and quality standards to help drive customer satisfaction and success. Other investments include new integrated business processes that span the entire clinical supply chain and cutting-edge technology solutions including interactive voice response/interactive web response (IVR/IWR) services. “Bilcare has built its reputation on providing customers with the highest-quality clinical supplies and research services, delivered on time, every time,” said Mangiardi. “Our new headquarters will allow us to take our services to the next level while continuing to provide the quality and attention that customers expect and deserve.” About Bilcare Global Clinical Supplies Bilcare Global Clinical Supplies serves the Americas, Europe, and Asia with clinical trial materials support, services, and complete project management. Its services for solid, semi-solid, liquid, DEA (CI-V) and biotech clinical trial materials (CTM) satisfy a broad range of requirements; from pre-formulation research and development, manufacturing, analytical services and clinical supplies packaging and labeling, to IVRS, QP services, controlled temperature (cold and frozen chain) CTM storage, distribution worldwide, and returns and destructions accountability. For more information about Bilcare Global Clinical Supplies, visit www.BilcareGCS.com. ## Media Contacts: Deborah Buscarino Director, Marketing & Communications Phone: 610-422-3204 Megan Maguire Kelly Schubert Communications, Inc. Phone: 610-269-2100 x225 Former Pfizer President and the Executive Director of Waterloo Institute of Nanotechnology as MembersPHOENIXVILLE, PA--(April 30, 2008) - Bilcare Global Clinical Supplies, a leading single-source provider of clinical trial services, has formed its first corporate Advisory Board. Bilcare Limited's Chairman and Managing Director Mohan Bhandari announced former Pfizer President John LaMattina, Ph.D., and Waterloo Institute of Nanotechnology Executive Director Arthur Carty, Ph.D., D.Sc., as the board's inaugural members. Dr. LaMattina will serve as its Chairman. The advisory board was created to provide the Bilcare GCS Senior Management Team with independent scientific industry expertise and insight to assist in the accomplishment of scientific and business objectives in support of the company's global mission. "The formation of our corporate Advisory Board is another major milestone in our mission to make Bilcare GCS the global leader in the clinical trial supplies arena," said Bhandari. "The addition of these accomplished members will prove to be a tremendous asset to research and innovation initiatives of our company."Dr. LaMattina had a distinguished 30-year career at Pfizer where he held various positions, including Senior Vice President of Pfizer Inc., and President of Pfizer Global Research and Development. In this role, Dr. LaMattina oversaw the drug discovery and development efforts of more than 12,000 colleagues in the United States, Europe and Asia. Dr. LaMattina is the author of 23 scientific publications and holds 15 U.S. patents. He is the 2004 recipient of the American Diabetes Association Award for Leadership and Commitment in the Fight Against Diabetes. Dr. LaMattina serves on the Board of Trustees of Boston College. "I am honored to be on the corporate Advisory Board of a company that is on the rise and gaining well-deserved recognition throughout the industry," said LaMattina. "I am confident that the Advisory Board will play a pivotal role in the future success of Bilcare's contribution to the clinical research industry." Dr. Carty is the first Executive Director of the Waterloo Institute of Nanotechnology and the former National Science Advisor to Canada's Prime Minister. A noted academic, Dr. Carty had a distinguished career as the President of the National Research Council of Canada from 1994 to 2004 after which he was appointed as the National Science Advisor. Prior to his recent return to the institute, Dr. Carty spent 27 years as a professor of chemistry at the University of Waterloo, serving as Chairman of the chemistry department and Dean of Research. He has authored more than 285 papers in refered journals and multiple book chapters and review articles, and also has five patents. Dr. Carty is a distinguished member of multiple boards including two for the Networks of Centres of Excellence and Genome Canada. Dr. Carty is both an Officer of the Order of Canada and Officer de L'Ordre National du Merite of France. "Serving on the corporate Advisory Board is an honor and comes with great responsibility," said Carty. "I am committed to providing technology and biotech expertise I can to Bilcare GCS to further its business objectives." "I am certain that both of our Board members with their extensive knowledge, experience, and business networks will provide immense benefits to our company," said Bilcare GCS CEO Vito Mangiardi. "We are honored to have Dr. LaMattina and Dr. Carty as an integral part of the Bilcare team and look forward to a long association with them and to their successful contribution especially in the areas of technology, research and innovation." Bilcare Global Clinical Supplies serves the Americas, Europe, and Asia with clinical trial materials support, services and complete project management. Our services for solid, semi-solid, liquid, DEA (CI-V) and biotech clinical trial materials (CTM) satisfy a broad range of requirements, from pre-formulation research and development, analytical services and clinical supplies packaging and labeling, to IVRS, controlled temperature (cold and frozen chain) CTM storage, distribution worldwide, and returns and destructions accountability. For more information about Bilcare Global Clinical Supplies, please visit our website at www.BilcareGCS.com. Media Contacts: Deborah Buscarino Director of Marketing Phone: 610-422-3204 Fax: 610-935-4321 E-mail: Email Contact Vito Mangiardi Chief Executive Officer Bilcare Global Clinical Supplies Phone: 610-551-2035 Fax: 610-935-4321 E-mail: Email Contact  Pune, 26 February, 2008 – Bilcare Global Clinical Supplies, [www.BilcareGCS.com] the single source provider of quality clinical trial materials from formulation and analytical services to IVRS and global distribution spread across the Americas, Europe and Asia has appointed Vito Mangiardi, a 30-year Industry veteran as the new CEO to lead the firm. Speaking on this momentous occasion, Mr. Mohan Bhandari, Chairman & Managing Director, Bilcare Ltd. said, “Vito is an exceptional leader and strategist. He has vast experience in global business management, pharmaceutical and biotech contract research and development services, and extensive expertise in clinical supplies. Vito’s breadth and depth of experience is unsurpassed in the industry and he is a perfect fit for Bilcare GCS as we continue to experience steady growth.” According to Mangiardi, “This is an honor and tremendous opportunity for me to add value to this booming enterprise.” Mangiardi has gained a wealth of experience in virtually all aspects of the clinical supplies, pharmaceutical and biotech industries. He has held key leadership positions throughout his career, most recently serving as President of North American Operations for AAI Pharma where he was responsible for Phase I, formulation development, analytical development, bio-analytical, manufacturing and stability testing, as well as Phase II-IV clinical trials. At AAI, Mangiardi grew the revenue line dramatically and turned the company results from a loss to a profit within two years. Prior to his joining AAI Pharma, Mangiardi had a very successful career at Quintiles Transnational as a Senior Vice President and Chief Operating Officer of Global Phase IV Services. He also held other executive level positions at Quintiles including head of the International Clinical Development Services group in Japan, head of the Asia Pacific Business and Executive Vice President of Operational Services of Quintiles Americas. Mangiardi has also served as President and CEO of Clingenix, Inc., an early stage pharmacogenomics company, and as President and CEO of Diagnostic Laboratories. The addition of Mangiardi’s expertise in pharmaceutical, biotech and clinical supplies and services is another key element of a major global initiative that Bilcare GCS started in 2007. The initiative was undertaken to allow the company to provide a higher level of quality and service to its customers. During the last several months, the company has made substantial improvements globally including upgrading equipment, increasing the number of its state-of-the-art packaging rooms, expanding its storage and distribution facilities, enhancing its formulation and analytical development services and technical capabilities, and integrating global operations. Other key milestones in the global initiative were Bilcare’s recent announcement of its commitment to invest £11million into a state-of-the art clinical supplies facility in South Wales and the inauguration of the Bilcare Centre of Excellence in Pune, India. Wales is an ideal location for Bilcare GCS to service the European market at a competitive cost. It will strengthen what is already a key location geographically and strategically for Bilcare GCS. The Centre of Excellence in India will have dedicated R&D sections for Packaging Research, Material Research, Analytical Research, Drug Sensitivity Studies and Package Design. To maximize the effectiveness of its capital campaign, Bilcare GCS also made significant additions to its global management team. Reporting to Mangiardi are three well respected industry veterans, David Laskow Pooley leading the company’s European operations, Vincent Santa Maria leading the American operations and Ajit Dubhashi leading the Asian operations. The company also added key management personnel globally in Sales, IT, IVRS, Project Management, Business Development, Operations, Formulation, Analytical Services and Finance. Bilcare Global Clinical Supplies serves the Americas, Europe, and Asia with clinical trial materials support, services and complete project management. Our services for solid, semi-solid, liquid, DEA (CI-V) and biotech clinical trial materials (CTM) satisfy a broad range of requirements; from pre-formulation research and development, analytical services and clinical supplies packaging and labeling, to IVRS, controlled temperature (cold and frozen chain) CTM storage, distribution worldwide, and returns and destructions accountability. For more information about Bilcare Global Clinical Supplies, please visit our website at www.BilcareGCS.com. For more information, contact: Corporate Information Contact : Jaydip Chowdhury, Head Corporate Communications [] Media Alert
Who: Bilcare Global Clinical Supplies What: Clinical Trials Outsourcing When: February 25-27, 2008 Where: Sixth Annual Clinical Trials Congress Booth 307 Royal Pacific Resort Orlando, Florida Media Contact: Brian Courtney, 610-269-2100 ext. 249; Blicare Global Clinical Supplies to Display Full Range of Clinical Trials Supplies and Services Bilcare Global Clinical Supplies {www.BilcareGCS.com} will be exhibiting its broad range of clinical trials supplies and services at the Sixth Annual Clinical Trials Congress (CTC). Bilcare GCS offers a seamless clinical supply chain encompassing the Americas through Europe to Asia. Bilcare ensures clinical trials success by continuously providing superior clinical trial material (CTM) services covering all phases of development, from formulation through IVRS and global distribution. This year’s meeting is called Mission Fast Track. CTC offers five primary educational courses and numerous breakouts and specialty sessions to help companies improve clinical trials processes and management. Editor’s Note: To set up a booth interview, please contact Brian Courtney at 610-269-2100, ext. 249, or . Bilcare Global Clinical Supplies US Facility Boasts 10 Primary and 16 Secondary Packaging Rooms[Phoenixville, PA] February 15, 2008--Bilcare Global Clinical Supplies, [www.BilcareGCS.com], the single source provider for global clinical supplies and services announced the completion of an important phase in its capital improvement program that substantially increased and upgraded the capacity and flexibility of its primary and secondary packaging rooms. The company has added six new state-of-the–art packaging rooms and upgraded 20 others. Bilcare GCS now has ten primary and sixteen secondary packaging rooms at its 153,000 square foot U.S. operation. “The expansion and upgrading of our facilities and equipment is part of an ongoing and comprehensive effort to provide world class service to our customers, said Bilcare Global Clinical Supplies, Americas, President Vincent Santa Maria. “Now more than ever Bilcare GCS has the capacity, expertise and capability to manage any project and to provide quality and service beyond compliance.”During the second half of 2007, Bilcare GCS expanded its storage and distribution facility (72,000 square feet), installed PRISYM Medica labeling system software, increased its stability storage capacity and its formulation and analytical service capacity, and enhanced its IVRS/IWRS capabilities. “These capital improvements combined with our experienced staff of project managers and our large global footprint in Europe and Asia sends a clear message to the industry that Bilcare GCS is the place for your clinical supply projects, said Santa Maria. Bilcare Global Clinical Supplies serves the Americas, Europe, and Asia with clinical trial materials support, services and complete project management. Our services for solid, semi-solid, liquid, DEA (CI-V) and biotech clinical trial materials (CTM) satisfy a broad range of requirements; from pre-formulation research and development, analytical services and clinical supplies packaging and labeling, to IVRS, controlled temperature (cold and frozen chain) CTM storage, distribution worldwide, and returns and destructions accountability. For more information about Bilcare Global Clinical Supplies, please visit our new website at www.BilcareGCS.com. ## Media Contacts: Vincent Santa Maria, CPA President Bilcare Global Clinical Supplies, Americas Phone: 610-422-3180 Fax: 610-935-4321 E-mail: Leading Clinical Trials Supplies Firm Renamed To Reflect Global Affiliation and CapabilitiesCrickhowell, Powys, Wales, UK—February 1, 2008--DHP Ltd. has been renamed Bilcare Global Clinical Supplies (Europe) Ltd. to reflect its position as an integral component of Bilcare Global Clinical Supplies [www.BilcareGCS.com]. Bilcare Global Clinical Supplies serves the Americas, Europe, and Asia with clinical trial materials support, services and complete project management. Bilcare, with offices in the US, India, Singapore and the UK, has the capability to distribute supplies into 50 countries worldwide. Mohan Bhandari, Bilcare Chairman, said, “The name change is fully consistent with our branding efforts and our mission to become the leading provider of global clinical supplies. It is also reflective of our ongoing program to improve our global capabilities and capacity.” To that end Bilcare recently announced that it will invest £11million into a new state-of-the art facility near its current facility in Crickhowell, South Wales. Customers can expect more capacity, a wider range of services and access to the latest technology.Bilcare acquired DHP in 2006 to bolster its presence in the EU market. The acquisition gave Bilcare the ability to meet the needs of global customers by providing quality support that enables them to manufacture, package, test, store and distribute clinical supplies in the EU. DHP, which has a proud reputation for service and quality, has been one of the leading providers of clinical trial services in the UK and Europe for over 19 years. Said Bilcare GCS (Europe) Ltd. President David Laskow-Pooley, “Changing our name to reflect our corporate parentage inextricably links us with a company that has a sterling worldwide reputation for quality and service.” Bilcare Global Clinical Supplies serves the Americas, Europe, and Asia with clinical trial materials support, services and complete project management. Our services for solid, semi-solid, liquid, DEA (CI-V) and biotech clinical trial materials (CTM) satisfy a broad range of requirements; from pre-formulation research and development, analytical services and clinical supplies packaging and labelling, to IVRS, controlled temperature (cold and frozen chain) CTM storage, distribution worldwide, and returns and destructions accountability. For more information about Bilcare Global Clinical Supplies, please visit our website at www.BilcareGCS.com. # Media Contacts: Vincent Santa Maria, CPA President Bilcare Global Clinical Supplies, Americas Phone: 610-422-3180 Fax: 610-935-4321 E-mail: Corporate Information Contact : Jaydip Chowdhury Head Corporate Communications [] Industry Veteran to be Vice President of SalesPhoenixville, PA--January 31, 2008—Bilcare Global Clinical Supplies, Americas {www.BilcareGCS.com} has added industry veteran Sandy Richwalski as its Vice President of Sales. Richwalski was most recently Vice President and General Manager of Catalent (formerly Cardinal Health). “We are excited to add Sandy to what is already an outstanding management team”, said Bilcare Inc. President, Vincent Santa Maria. “Her proven leadership skills and clinical supplies expertise will enhance the effectiveness of our very talented Sales Team.”Richwalski has gained a wealth of experience in the clinical supplies and pharmaceutical industry during her more than 25 year career. She has broad clinical supplies industry experience having worked for Quintiles as Vice President of Operations, Almedica Services as Director of Operations and both Ligand Pharmaceuticals and AAI as Clinical Supplies Manager. She also has extensive experience in the pharmaceutical industry having worked in various management positions with Schering-Plough, Boots and Best Generics. Bilcare Global Clinical Supplies serves the Americas, Europe, and Asia with clinical trial materials support, services and complete project management. Our services for solid, semi-solid, liquid, DEA (CI-V) and biotech clinical trial materials (CTM) satisfy a broad range of requirements; from pre-formulation research and development, analytical services and clinical supplies packaging and labeling, to IVRS, controlled temperature (cold and frozen chain) CTM storage, distribution worldwide, and returns and destructions accountability. For more information about Bilcare Global Clinical Supplies, please visit our new website at http://www.BilcareGCS.com/ ## Media Contacts: Vincent Santa Maria, CPA President Bilcare Global Clinical Supplies, Americas Phone: 610-422-3180 Fax: 610-935-4321 E-mail: Corporate Information Contact : Jaydip Chowdhury Head Corporate Communications [] David Laskow-Pooley to Head EU Region of Leading Clinical Supplies CompanyFebruary 1, 2008-(Crickhowell, Powys Wales, UK)—David Laskow-Pooley, MRPharmsS, QP, former CEO of Surface Therapeutics has joined Bilcare Global Clinical Supplies (Europe) Ltd. (www.BilcareGCS.com) as President. Laskow-Pooley will head the EU Region of Bilcare GCS, a global firm which also has offices in the US, India and Singapore. A subsidiary of Bilcare Limited headquartered in Pune, India, Bilcare GCS is a leading provider of the packaging and global distribution of clinical trial materials. “David is a tremendous addition to our team”, said Bilcare Limited Chairman and Managing Director, Mohan Bhandari. “His wealth of global industry experience and the depth of his expertise is a perfect fit for our expanding European operation.”Laskow-Pooley has 30 years of experience in all aspects of the discovery, development and commercialization of Pharmaceutical and healthcare products. He has had a distinguished career in the industry working for a number of pharmaceutical and life sciences companies including GlaxoSmithKline, Abbott, Invitrogen and Amersham in Europe, the US and Japan, and OSI Pharmaceuticals. He was previously CEO of Surface Therapeutics Ltd., a start up company spun out of the University of Oxford which recently sold to Serentis Ltd. Laskow-Pooley has a degree in pharmacy, specializing in industrial pharmacy and chemical engineering and is a registered Qualified Person. He is chair of the steering group of the Oxfordshire Bioscience Network and an independent Governor of Oxford Brookes University. Bilcare Global Clinical Supplies serves the Americas, Europe, and Asia with clinical trial materials support, services and complete project management. Our services for solid, semi-solid, liquid, DEA (CI-V) and biotech clinical trial materials (CTM) satisfy a broad range of requirements; from pre-formulation research and development, analytical services and clinical supplies packaging and labeling, to IVRS, controlled temperature (cold and frozen chain) CTM storage, distribution worldwide, and returns and destructions accountability. For more information about Bilcare Global Clinical Supplies, please visit our website at www.BilcareGCS.com. ## Media Contacts: Vincent Santa Maria, CPA President Bilcare Global Clinical Supplies, Americas Phone: 610-422-3180 Fax: 610-935-4321 E-mail: Corporate Information Contact : Jaydip Chowdhury Head Corporate Communications [] Bilcare’s research product makes counterfeit drug virtually impossiblePune, India: Former President of India, Dr. APJ Abdul Kalam and Dr. John L. LaMattina (Senior Vice President, Pfizer Inc and President, Pfizer Global Research & Development) inaugurated the Bilcare Centre of Excellence . The Centre will have dedicated R&D sections for Packaging Research, Material Research, Analytical Research, Drug Sensitivity Studies and Package Design. For converting the innovations into reality, the centre is also equipped with Asia’s first integrated Flexo Printing machine and a State-of-the art pilot plant which was inaugurated by Dr. R Chidambaram, Principal Scientific Advisor to Government of India.According to the World Health Organization (WHO) 10% of global medicines, worth $50Bn are counterfeit and $150Bn revenue loss due to compliance related issues. To combat this global crisis, Bilcare Research has developed a unique product which was also jointly launched by Dr. APJ Abdul Kalam & Dr. John L. LaMattina. This product will help the pharmaceutical industry in securing their brands, increasing every product’s warranty ,traceability and secure the supply chain management apart from eradicating counterfeit and ensuring better healthcare compliance. Speaking on the occasion, Mr. Mohan Bhandari, Chairman & Managing Director, Bilcare Limited, said ‘Bilcare is emerging fast as a knowledge company with unique research capabilities to address critical challenges of the pharmaceutical Industry. With this product and the R&D center launch, we are now in a position to offer complete solution to our global customers on counterfeit and ensure better healthcare for tomorrow.’ Out of major investments in nanotechnology research & development happening today, this is one of the first cost effective and useful solution for the common man offered by Bilcare. About Bilcare: Headquartered in India, Bilcare provides integrated packaging solutions across the entire spectrum of pharmaceutical value chain through five focused business activities – Research Services, Clinical Supplies, Design Lab, Research Academy and Packaging Materials. Bilcare operates state-of-the art manufacturing facilities in India, Singapore, US & UK and has regional offices in Brazil, Germany, China & Australia which caters to global clients including J&J, Merck, GSK, Sanofi, Pfizer, Novartis, Wyeth, Ranbaxy, Dr. Reddy to name a few. Bilcare Research is increasingly changing the face of pharma industry by enabling global pharmaceuticals companies and their brands with better communication, patient compliance, cost, convenience and checking counterfeit through its innovative solutions. For more information contact: Jaydip Chowdhury E-mail: Head Corporate Communications Bilcare Research MUMBAI, INDIA) - The Deputy First Minister of the Welsh Assembly Government Ieuan Wyn Jones, who is currently leading a delegation of Welsh companies in India, announced that Bilcare, the Pune-based pharmaceutical packaging-to-clinical research company, will invest £ 11 million in setting up a new clinical supplies facility in South Wales. The new facility will replace the existing clinical supplies facility acquired by Bilcare in 2006.
First Minister Jones and Mohan Bhandari, Chairman and Managing Director, Bilcare, signed the agreement today in Mumbai. The investment will enable Bilcare to expand its presence in Wales and cater to the needs of its customers in Western Europe and parts of Eastern Europe. Wales is well positioned to provide a central location in Europe for Bilcare -- just two hours away from London. With University research excellence, good availability of key skills -- from laboratory staff to PhDs -- superior infrastructure and a network that links companies, academics and government together, Wales is an ideal location for Bilcare to service the European market at a competitive cost. Commenting on Bilcare's investment in Wales, Minister Jones said, "Wales is an ideal location for companies in the pharmaceutical and biosciences space. The Welsh economy is driven by high technology sectors like biotechnology, opto electronics and aerospace. "Wales is strategically located to provide a true gateway to the rest of Europe. Our endeavour is to encourage companies like Bilcare to set up in Wales as we have the ideal environment for technology transfers, collaboration and product licenses with the best academic support and R&D expertise. We provide companies with a real opportunity to excel and reach out to their customers in Europe in a competitive environment. We are delighted that Bilcare will establish its new facility in Wales." Bhandari said, "We have aggressive plans for Europe and Wales is a good base from which to operate in Europe. We acquired DHP, a clinical supplier last fiscal year and now with our new facility will employ around 200 people in Wales. With the support of the Welsh Government and International Business Wales, we have been able to expedite the process of expansion in Wales for servicing the European market." Indian companies in Wales include: Bilcare, BUI Pvt Ltd - Universal Batteries, Indo Fuji, RR Auto and Wockhardt. About International Business Wales (IBW) International Business Wales is the expert team that helps make profitable connections between Wales and ambitious companies globally. Whether a company wants to trade or invest, the IBW team has the experience and skill to enable companies to forge the relationships they need to expand their business in the global market. About Bilcare: Headquartered in India, Bilcare provides integrated packaging solutions across the entire spectrum of pharmaceutical value chain through five focused business activities -- Research Services, Clinical Supplies, Design Lab, Research Academy and Packaging Materials. Bilcare operates state-of-the art manufacturing facilities in India, Singapore, US & UK and has regional offices in Brazil, Germany, China & Australia which caters to global clients including J&J, Merck, GSK, Sanofi, Pfizer, Novartis, Wyeth, Ranbaxy, Dr. Reddy to name a few. Bilcare Research is increasingly changing the face of the pharma industry by enabling global pharmaceuticals companies and their brands with better communication, patient compliance, cost, convenience and checking counterfeit through its innovative solutions. For more details contact: R&PM: Edelman (Mumbai) Ophira Samuel-Bhatia/Melanie D'sa Tel: +91 22810168-72 Mobile: +91 98202 20116/+91 9892077534 Email: Email Contact/Email Contact R&PM: Edelman (New Delhi) Arun Mowar Tel: +91 11 2332 0116 Mobile: +91 9810948319 Email: Email Contact Corporate Information Contact: Jaydip Chowdhury Head Corporate Communications Email Contact: [] |
|
| News from BilcareView Past News |
